Phase I clinical study of FC084CSA, a high selective AXL kinase inhibitor that ameliorates tumor microenvironment and augments the effectivity of immunotherapy.
Journal of Clinical Oncology2024cited by 1position: middledoi
Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
International Journal of Clinical Practice2022cited by 6position: lastdoi